3 completed, 1 active not recruiting, 1 withdrawn. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Recurrent Breast Cancer: new trials by email Literature Review of Recurrent Breast Cancer trials Research Report on Recurrent Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery fulvestrant, anastrozole - Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 1473 | 2014-02-27 | 2026-06-05 |
| Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer [18F]fluoroestradiol (FES) - Recurrent Breast Cancer, Stage IV Breast Cancer | Phase 3 | Completed | Asan Medical Center | 93 | 2013-11-01 | 2016-12-08 |
| Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) nab-Paclitaxel, Carboplatin, Gemcitabine - Breast Tumor, Breast Cancer | Phase 2 / Phase 3 | Completed | Celgene | 191 | 2013-09-26 | 2019-02-21 |
| Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic paclitaxel, trastuzumab, quality-of-life assessment - HER2-negative Breast Cancer, HER2-positive Breast Cancer | Phase 3 | Completed | National Cancer Institute (NCI) | 580 | 1998-07-01 | 2013-06-04 |
| Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer tamoxifen, trastuzumab - Stage IV Breast Cancer, Recurrent Breast Cancer | Phase 3 | Withdrawn | Alliance for Clinical Trials in Oncology | 2016-07-12 |
Breast Neoplasms (5) · Carcinoma, Ductal, Breast (1) · Carcinoma, Lobular (1) · Triple Negative Breast Neoplasms (1)
Breast Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Ductal (1) · Neoplasms by Histologic Type (1) · Neoplasms, Ductal, Lobular, and Medullary (1) · Neoplasms, Glandular and Epithelial (1)
Trastuzumab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Anastrozole (1) · Carboplatin (1) · Fulvestrant (1) · Gemcitabine (1) · Paclitaxel (1) · Tamoxifen (1) · Taxes (1)
Alliance for Clinical Trials in Oncology (2) · Asan Medical Center (1) · Celgene (1) · National Cancer Institute (NCI) (1)
United States (3) · Australia (1) · Austria (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · Portugal (1) · Puerto Rico (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Andrew Seidman (1) · Cynthia Ma, MD, PhD (1) · Dae Hyuk Moon, MD. PhD (1) · Ileana Elias, M.D. (1) · Joanne E. Mortimer, MD (1)
PMID 28045625, PMID 30846327, PMID 31849532, PMID 38236590
U10CA031946 (2)